Skip to main content
NCBI home page
Indian Journal of Clinical Biochemistry logoLink to Indian Journal of Clinical Biochemistry
. 2007 Mar;22(1):4–9. doi: 10.1007/BF02912873

Brain type natriuretic peptide (BNP)—A marker of new millennium in diagnosis of congestive heart failure

Arun Raizada 1,✉, Suman Bhandari 1, Muzaiyan Ahmed Khan 2, Harsh Vardhan Singh 3, Sherin Thomas 1, Vikram Sarabhai 1, Neelima Singh 4, Naresh Trehan 1
PMCID: PMC3454260  PMID: 23105644

Abstract

The burden of disease in patients with congestive heart failure is high. The future of BNP looks promising as it may be a better diagnostic tool for the diagnosis of CHF in developing countries in new millennium. Natriuretic peptide hormones, a family of vasoactive peptides with many favourable physiological properties, have emerged as important contenders for development of diagnostic tools and therapeutic agents in cardiovascular disease. Measurement of B-type natriuretic peptide has become as an easy-to-perform bedside test. The clinical and diagnostic significance of the measurement of plasma Nt-proBNP in the diseases of the cardiovascular system with particular emphasis on the assessment of patients with heart failure and their effects on predicting survival rate. The plasma levels of Nt-proBrain Natriuretic peptide responds more vigorously after myocardial infarction than those of other natriuretic peptides. This article is an attempt to give a short overview on the utility of BNP-blood levels for the diagnosis and treatment of heart failure

Key words: Congestive heart failure, B-type Natriuretic peptide, Amino terminal pro brain natriuretic peptide, Left ventricular ejection fraction, Myocardial Infarction

Full Text

The Full Text of this article is available as a PDF (72.4 KB).

References

  • 1.Dorothea KT, Apostolos IK, Kostas GR, Aspostolos Z. Brain natriuretic peptide. Hell J card. 2003;44:266–70. [Google Scholar]
  • 2.Sudoh T, Kangawa K, Miniamo N. A new natriuretic peptide in porcine brain. Nature. 1988;332:78–81. doi: 10.1038/332078a0. [DOI] [PubMed] [Google Scholar]
  • 3.Kambayashi Y, Nakaoka K. Isolation and sequence determination of human BNP. Febs letters. 1990;259:341–5. doi: 10.1016/0014-5793(90)80043-I. [DOI] [PubMed] [Google Scholar]
  • 4.Pfister R, Schneider CA. Natriuretic peptides BNP and NT-pro-BNP: established laboratory markers in clinical practice or just perspectives? Clin Chim Acta. 2004;349(1–2):25–38. doi: 10.1016/j.cccn.2004.06.018. [DOI] [PubMed] [Google Scholar]
  • 5.Thurpraf DJ, Glembotski CC. Differential effects of protein kinase C, Ras and Raf-1 kinase on induction of the cardiac B-type natriuretic peptide gene through a critical promotor-proximal M-CAT element. J Biol Chem. 1997;272:7464–72. doi: 10.1074/jbc.272.11.7464. [DOI] [PubMed] [Google Scholar]
  • 6.Ogowa E. Fibronectin signaling stimulates BNP gene transcription by inhibiting neuron-restrictive silencere element dependent system repression. Cardiovascular Res. Commun. Cardiovascular Res. 2001;53:451–9. doi: 10.1016/s0008-6363(01)00492-8. [DOI] [PubMed] [Google Scholar]
  • 7.Hautala N. Pressure overload increase GATA 4 binding activity via endothelin I. Circulation. 2001;103:730–5. doi: 10.1161/01.cir.103.5.730. [DOI] [PubMed] [Google Scholar]
  • 8.Tsutamoto T. Attenuation of compensation of endogenous cardiac natriuretic peptides system in chronic heart failure. Circulation. 1997;96:509–16. doi: 10.1161/01.cir.96.2.509. [DOI] [PubMed] [Google Scholar]
  • 9.Wei CM. Natriuretic peptide system in human heart failure. Circulation. 1993;88:1004–9. doi: 10.1161/01.cir.88.3.1004. [DOI] [PubMed] [Google Scholar]
  • 10.Christopher B, Granger Effects of candersaritan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotens in converting enzyme (ACE) inhibitors. The CHARMS—Alternative trial. Lancet. 2003;326:772–6. doi: 10.1016/S0140-6736(03)14284-5. [DOI] [PubMed] [Google Scholar]
  • 11.Yoshimura M. B-tNP as a marker of effects of enalapril in patients with heart failure. Am J Med. 2002;112:716–30. doi: 10.1016/S0002-9343(02)01121-X. [DOI] [PubMed] [Google Scholar]
  • 12.Yamamoto K. Superiority of BNP as a hormonal markers of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996;28:988–94. doi: 10.1161/01.hyp.28.6.988. [DOI] [PubMed] [Google Scholar]
  • 13.Troughton RW. Treatment of heart failure guided by plasma amino terminal brain natriuetic peptides (Nt-BNP) concentrations. Lancet. 2000;355:1126–30. doi: 10.1016/S0140-6736(00)02060-2. [DOI] [PubMed] [Google Scholar]
  • 14.Yasue H, Yoshimura M. Localization and mechanism of secretion of B-type natriuretic peptides in comparison with those of A type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195–203. doi: 10.1161/01.cir.90.1.195. [DOI] [PubMed] [Google Scholar]
  • 15.Omnland T, Aakvaag A. Plasma brain natriuretic peptides as an indicator of Left ventricular systolic function and long term survival after acute myocardial infarction. Comparison with plasma ANP and N terminal pro atrial natriuretic peptides. Circulation. 1996;93:1963–9. doi: 10.1161/01.cir.93.11.1963. [DOI] [PubMed] [Google Scholar]
  • 16.Kuchner N, Printzen G, et al. Low pro-brain natriuretic peptide benign clinical outcome in acute pulmonary embolsim. Circulation. 2003;1(12):1576–1578. doi: 10.1161/01.CIR.0000064898.51892.09. [DOI] [PubMed] [Google Scholar]
  • 17.Thurpraf DJ, Glembotski CC. Differential effects of protein kinase C, Ras and Raf-1 kinase on induction of the cardiac B-type natriuretic peptide gene through a critical promotor-proximal M-CAT element. J Biol Chem. 1997;272:7464–72. doi: 10.1074/jbc.272.11.7464. [DOI] [PubMed] [Google Scholar]
  • 18.Wu AH, Smith A, Wieczorrek S, Mather JF, Duncan B, White CM, McGill Katten D. Biological variations for NT-pro & BNP and implications for therapeutic monitoring of patients with congestive heart failure. Hel Am J Car. 2003;92(5):628–31. doi: 10.1016/S0002-9149(03)00741-0. [DOI] [PubMed] [Google Scholar]
  • 19.Henricksen JH, Gotze JP, Fuglsang S, Christensen E, Bendtsen F, Mollers Increased circulating proBNP and BNP in patients with cirrhosis related to cardiovascular dysfunction and severity of disease. Gut. 2003;52(10):1511–7. doi: 10.1136/gut.52.10.1511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Gottelib SS. Prognostic importance of aterial natriuretic peptide in patients with chronic heart failure. JACC. 1989;13:1534–9. doi: 10.1016/0735-1097(89)90344-6. [DOI] [PubMed] [Google Scholar]
  • 21.Lemos JA, Morrow DA. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014–21. doi: 10.1056/NEJMoa011053. [DOI] [PubMed] [Google Scholar]
  • 22.Fisher C, Berry C, Blue L, Morton JJ, McMurray J. N-tproB-NP, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart. 2003;89(8):879–81. doi: 10.1136/heart.89.8.879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.James SK, Lindhal B, Siegalbhan A. Nt proBNP and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. GUSTO-IV sub study. Circulation. 2003;108(3):275–81. doi: 10.1161/01.CIR.0000079170.10579.DC. [DOI] [PubMed] [Google Scholar]
  • 24.Moser P, Stanek B, Pacher R. BNP predicts sudden death in patients with chronic heart failure. Circulation. 2002;105:2392–7. doi: 10.1161/01.CIR.0000021745.45349.BB. [DOI] [PubMed] [Google Scholar]
  • 25.Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92(6):843–9. doi: 10.1136/hrt.2005.071233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Nakamura M, Endo H. Value of plasma B-type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart. 2002;87(2):131–5. doi: 10.1136/heart.87.2.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Isabgel H., Jose L., Arneau MA, et el. Ventricular natriuretic peptides (BNP) in heart transplantation; BNP correlation with endomyocardial bioipsy, laboratory and heamodynamic measures. Laboratory Invest 2003 p. 1–8. [DOI] [PubMed]
  • 28.Holtwick R. Pressure independent cardiac hypertrophy in mice with cardiomyocyte restricted inactivation of the atrial natriuretic peptide receptor Guanyl cyclase. J Clin. Invest. 2003;111:1399–1407. doi: 10.1172/JCI17061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Buckley MG, Markandu ND. Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-dependent or dialysis independent chronic renal failure. Clin Investigation. 1992;83:437–44. doi: 10.1042/cs0830437. [DOI] [PubMed] [Google Scholar]
  • 30.Kohno M, Horio T, Yokokowa K, Murakawa K. Brain natriuretic peptide as a novel cardiac hormone in essential hypertension. Am J Med. 1992;201:29–34. doi: 10.1016/0002-9343(92)90011-Y. [DOI] [PubMed] [Google Scholar]
  • 31.Yandle TG, Richards AM, Gilbert A. Assay of brain natriuretic peptide in human plasma: Evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin. Endocrinol Metab. 1993;76:832–38. doi: 10.1210/jc.76.4.832. [DOI] [PubMed] [Google Scholar]
  • 32.Lang CC, Coutie WJ, Khong TK, Choy AM. Dietary sodium loading increases plasma brain natriuretic peptide levels in man. J Hypertens. 1991;9:779–82. doi: 10.1097/00004872-199109000-00002. [DOI] [PubMed] [Google Scholar]
  • 33.Matsumo A. Effects of exercise on plasma level of BNP in CHF with and without left ventricular dysfunction. Am Heart J. 1995;129:139–45. doi: 10.1016/0002-8703(95)90054-3. [DOI] [PubMed] [Google Scholar]
  • 34.Ikeda T, Matsuda K, Itoh H. Plasma levels of brain natriuretic peptides and atrial natriuretic peptide elevate in proportion to left ventricular end systolic wall stress in patients with aortic stenosis. Am Heart J. 1997;133:307–14. doi: 10.1016/S0002-8703(97)70225-4. [DOI] [PubMed] [Google Scholar]
  • 35.Thurpaf DJ, Glembotski CC. Differential effects of protein kinase C, RAS and RAF-1 kinase on induction of the cardiac B-type natriuretic peptide gene through a critical promotor-proximal M-CAT element. J Biol. Chem. 1997;272:7464–72. doi: 10.1074/jbc.272.11.7464. [DOI] [PubMed] [Google Scholar]
  • 36.Hasegawa K, Fujiwara H, Doyama K, Miyamae M. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation. 1993;88:372–80. doi: 10.1161/01.cir.88.2.372. [DOI] [PubMed] [Google Scholar]
  • 37.Morita E, Yasue H, Yoshimura M, Ogawa H. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation. 1993;88:82–91. doi: 10.1161/01.cir.88.1.82. [DOI] [PubMed] [Google Scholar]
  • 38.Buckley MG, Markandu ND. Brain and atrial natriuretic peptides: a dual peptide system of potential importance in sodium balance and blood pressure regulation in patients with essential hypertension. J Hypertens. 1994;12:809–13. doi: 10.1097/00004872-199407000-00013. [DOI] [PubMed] [Google Scholar]
  • 39.Melanson SE, Lewandrowski EL. Laboratory testing for B-type natriuretic peptides (BNP and NT-proBNP): clinical usefulness, utilization, and impact on hospital operations. Am J Clin Pathol. 2005;124 Suppl:122–8. doi: 10.1309/EU0G395MYPWNTND7. [DOI] [PubMed] [Google Scholar]

Articles from Indian Journal of Clinical Biochemistry are provided here courtesy of Springer

RESOURCES